Shares of biopharma MedImmune
With MedImmune's over $10 billion market capitalization, there aren't a whole lot of fish in the biotech and pharmaceutical sea that could afford to buy the company. Of course big pharmas like Pfizer
A good place to start looking for possible buyers of a biotech are with its partners. MedImmune has a marketing agreement with Abbott Laboratories
It's worth pointing out that plenty of other drug companies, like ImClone Systems
Looking for more Foolish drug stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.
Fool contributor Brian Lawler is not looking to be acquired and does not own shares of any company mentioned in this article. GlaxoSmithKline is an Income Investor recommendation. Pfizer is an Inside Value selection. The Fool has a disclosure policy.